| Drug Name |
Bevacizumab |
| Drug ID |
BADD_D00268 |
| Description |
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.[A192834,A192888,A192837,A192891,A192894]
In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market.[A193272,A193275] It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A.[A192888,A192939] Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer.[L12648]
Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI).[L12699] As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.[L12699] |
| Indications and Usage |
As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. |
| Marketing Status |
Prescription |
| ATC Code |
L01FG01; S01LA08 |
| DrugBank ID |
DB00112
|
| KEGG ID |
D06409
|
| MeSH ID |
D000068258
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D04KBL
|
| NDC Product Code |
50242-060; 50242-059; 63552-113; 50242-061; 58394-095; 50242-160; 63552-114 |
| Synonyms |
Bevacizumab | Mvasi | Bevacizumab-awwb | Bevacizumab awwb | Avastin |
